AmDerma Pharmaceuticals Exercises Option to License Rights to Oculus Innovative Sciences Acne Drug Candidate

Oculus Innovative Sciences, Inc. OCLS announced today that AmDerma Pharmaceuticals, the parent company of Quinnova Pharmaceuticals, Inc., an alliance member of Amneal Enterprises, has exercised its option to license rights to Oculus' Microcyn-based acne drug candidate. AmDerma and Oculus expect to finalize the terms of the license agreement within 45-60 days.